Inventor
Michael M. Miller
Inventor
Pennington, NJ, US
Overview
Patents· 21 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
A61KPreparations for medical, dental or toiletry purposes19%
C07DHeterocyclic compounds12%
C07KPeptides11%
Y02ATechnologies for adaptation to climate change8%
C07BGeneral methods of organic chemistry5%
G01NInvestigating or analysing materials by determining their chemical or physical properties5%
Y02PClimate change mitigation technologies in the production or processing of goods5%
C07CAcyclic or carbocyclic compounds4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
PatentTitleYear
11,067,732Virtual and augmented reality systems and methods202111,036,620Virtualization of ephemeral organization structures in a multitenant environment202110,822,343Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation202010,538,555Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions202010,450,347Immunomodulators201910,428,077Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation201910,358,463Immunomodulators201910,143,746Immunomodulators201810,047,103Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation20189,944,678Immunomodulators20189,879,046'Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions'20189,862,730'Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation'20189,850,283Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions20179,688,695'Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation'20179,605,022'Macrocyclic compounds for inhibition of inhibitors of apoptosis'20179,518,064'Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation'20169,308,236'Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions'20168,642,576'Heterocyclic CETP inhibitors'20148,304,403'Heterocyclic CETP inhibitors'20127,888,376'Heterocyclic CETP inhibitors'20117,790,770'Heterocyclic CETP inhibitors'2010Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2010–2020Patents assigned to BRISTOL MYERS SQUIBB CO (18)· patent assignee history
2010–2020Based in Pennington, NJ, US· patent location history
2012–2014Patents assigned to CHEN BANG-CHI (2)· patent assignee history
2012–2014Patents assigned to FINLAY HEATHER (2)· patent assignee history
2012–2014Patents assigned to HARIKRISHNAN LALGUDI S (2)· patent assignee history
2016–2020Patents assigned to UNIV MONTREAL (6)· patent assignee history
2017–2020Based in Lambertville, NJ, US· patent location history
2017Based in Princeton, NJ, US· patent location history
2021Based in Austin, TX, US· patent location history
2021Based in Boulder, CO, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BRISTOL MYERS SQUIBB CO | 18 | 2010–2020 |
| UNIV MONTREAL | 6 | 2016–2020 |
| CHEN BANG-CHI | 2 | 2012–2014 |
| FINLAY HEATHER | 2 | 2012–2014 |
| HARIKRISHNAN LALGUDI S | 2 | 2012–2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| Pennington, New Jersey, US | 11 | 2010–2020 |
| Lambertville, New Jersey, US | 7 | 2017–2020 |
| Austin, Texas, US | 1 | 2021 |
| Boulder, CO, US | 1 | 2021 |
| Princeton, New Jersey, US | 1 | 2017 |